ABBV
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- AbbVie and Genmab's epcoritamab plus R-CHOP delivers significant progression-free survival benefit in a frontline lymphoma trialOct 6, 2026
- AbbVie's long-acting anti-IL-13 antibody zumilokibart meets the efficacy target in a Phase 2b atopic dermatitis trialSep 30, 2026
- FDA approves AbbVie’s JUVMO (tavapadon) for the treatment of Parkinson’s diseaseSep 28, 2026
- EPKINLY receives Health Canada approval for adults with follicular lymphomaSep 24, 2026
- AbbVie receives European Commission approval for RINVOQ (upadacitinib) to treat active polyarticular juvenile idiopathic arthritis in childrenSep 22, 2026